Venlafaxine ER Blocks the Norepinephrine Transporter in the Brain of Patients with Major Depressive Disorder: a PET Study Using [18F]FMeNER-D2
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The in vivo binding of clinical dose of venlafaxine on norepinephrine transporter has been questioned because venlafaxine has higher in vitro affinity to serotonin transporter than that to norepinephrine transporter. Although serotonin transporter occupancy of clinically relevant doses of venlafaxine has been reported, there has been no report of norepinephrine transporter occupancy in the human brain. METHODS: This was an open-label, single center, exploratory positron emission tomography study. Twelve major depressive disorder patients who had responded to venlafaxine extended-release and 9 control subjects were recruited. Each subject participated in one positron emission tomography measurement with [18F]FMeNER-D2. Binding potential in brain was quantified by the area under the curve ratio method with thalamus as target and white matter as reference regions. The difference of binding potential values between control and patient groups divided to 2 dose ranges were evaluated. Norepinephrine transporter occupancy (%) for all the major depressive disorder patients was calculated using mean binding potential of control subjects as baseline. The relationships between dose or plasma concentration of total active moiety and occupancies of norepinephrine transporter were also estimated. RESULTS: The binding potential of the patient group with 150 to 300 mg/d was significantly lower than that in the control subjects group (P = .0004 < .05/2). The norepinephrine transporter occupancy (8-61%) increased in a dose-dependent manner although a clear difference beyond 150 mg/d was not observed. CONCLUSIONS: This study demonstrates that clinically relevant doses of venlafaxine extended-release block the norepinephrine transporter of the major depressive disorder patient's brain. The data support the notion that the antidepressant effect of venlafaxine involves a combination of serotonin transporter and norepinephrine transporter blockades.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“First, SNRIs inhibit the norepinephrine transporter (NET), which prevents the reuptake of NE into presynaptic neurons, leading to an increased concentration of NE in the synaptic cleft. 370”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [370]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Bymaster, F. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00298-6 · Cited by 717
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517
Reduced Levels of Norepinephrine Transporters in the Locus Coeruleus in Major Depression
Klimek, V., Stockmeier, C., Overholser, J., Meltzer, H. Y., Kalka, S., Dilley, G., & Ordway, G. A. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-21-08451.1997 · Cited by 445 · cited 1×
“Postmortem data, and recently also in vivo data, suggest changes in NET densities in MDD subjects (Klimek et al., 1997; Moriguchi et al., 2017b).”
BackgroundLocher, C., Koechlin, H., Zion, S. R., Werner, C., Pine, D. S., Kirsch, I., Kessler, R. C., & Kossowsky, J. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.2432 · Cited by 360
Meyer, J. H., Wilson, A. A., Ginovart, N., Goulding, V., Hussey, D., Hood, K., & Houle, S. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1843 · Cited by 340
Nelson, J. C. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810280019002 · Cited by 294
Papakostas, G. I., Fava, M., & Thase, M. E. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.08.010 · Cited by 284
Meta-analysis of molecular imaging of serotonin transporters in major depression
Gryglewski, G., Lanzenberger, R., Kranz, G. S., & Cumming, P. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.82 · Cited by 227 · cited 1×
“, the serotonin transporter (5-HTT) (Savitz and Drevets, 2013; Gryglewski et al., 2014).”
Cited by
Major depressive disorder: hypothesis, mechanism, prevention and treatment
Cui, L., Li, S., Wang, S., Wu, X., Liu, Y., Yu, W., Wang, Y., Tang, Y., Xia, M., & Li, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01738-y · Cited by 1,244
“370 Second, similar to SSRIs, SNRIs also inhibit SERT, resulting in an increased concentration of 5-HT in the synaptic cleft.”
BackgroundAntidepressant Drugs Effects on Blood Pressure
Calvi, A., Fischetti, I., Verzicco, I., Murri, M. B., Zanetidou, S., Volpi, R., Coghi, P., Tedeschi, S., Amore, M., & Cabassi, A. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.704281 · Cited by 176
“At lower doses, the inhibition of 5-HT reuptake prevails, whereas at high doses (over 225mg) venlafaxine mainly acts as a NE reuptake inhibitor (100, 101).”
BackgroundBehlke, L. M., Lenze, E. J., & Carney, R. M. (2020) · CNS Drugs · doi:10.1007/s40263-020-00763-z · Cited by 135
Neuroinflammation and Natural Antidepressants: Balancing Fire with Flora
Figueiredo Godoy, A. C., Frota, F. F., Araújo, L. P., Valenti, V. E., Pereira, E. D. S. B. M., Detregiachi, C. R. P., Galhardi, C. M., Caracio, F. C., Haber, R. S. A., Fornari Laurindo, L., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13051129 · Cited by 32
“However, alternative classes such as serotonin–norepinephrine reuptake inhibitors (SNRIs), TCAs, monoamine oxidase inhibitors (MAOIs), and N-methyl-D-aspartate (NMDA) antagonists provide additional therapeutic pathways, especially in treatment-Biomedicines resistant cases [10,200–202].”
Chen, X., Kudo, T., Lapa, C., Buck, A. K., & Higuchi, T. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02180-4 · Cited by 44
Lense, X. M., Hiemke, C., Funk, C. S. M., Havemann‐Reinecke, U., Hefner, G., Menke, A., Mößner, R., Riemer, T., Scherf‐Clavel, M., Schoretsanitis, G., et al. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06484-7 · Cited by 40
“Four neuroimaging studies investigated SERT ( k = 3, n = 42) or NET ( k = 1, n = 21) occupancy in subjects treated with VEN (Frankle et al. 2018; Arakawa et al. 2019a; Meyer et al. 2004; Shang et al. 2007) (data supplement, table S8).”
BackgroundKringen, M. K., Bråten, L. S., Haslemo, T., & Molden, E. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001174 · Cited by 37
“Concentrations above this level indicates a transporter occupancy of 40% to 60% and more than 80% for the norepinephrine and serotonin transporters, respectively.(17,18) For the serotonin transporter, occupancy of 80% is considered as necessary for obtaining antidepressant effect.”
BackgroundThe utility of PET imaging in depression
Singh, S. B., Tiwari, A., Katta, M. R., Kafle, R., Ayubcha, C., Patel, K. H., Bhattarai, Y., Werner, T. J., Alavi, A. A., & Revheim, M.-E. R. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1322118 · Cited by 37
PET technology for drug development in psychiatry
Arakawa, R., Takano, A., & Halldin, C. (2020) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12084 · Cited by 26
Self-citationYang, R., Wang, L., Jin, K., Cao, S., Wu, C., Guo, J., Chen, J., Tang, H., & Tang, M. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.876152 · Cited by 26
Singh, N., Hazari, P. P., Mittal, P., Yadav, S. K., Kumar, N., Mishra, G., Dahiya, S., & Mishra, A. K. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177737 · Cited by 24
Aldosary, F., Norris, S., Tremblay, P., James, J. S., Ritchie, J., & Blier, P. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab086 · Cited by 25
“In contrast, using PET imaging of the NET, recent results indicate that doses >150 mg/d of venlafaxine did not show greater occupancy (Arakawa et al., 2019).”
ResultEffect of Venlafaxine on Apnea-Hypopnea Index in Patients With Sleep Apnea
Schmickl, C. N., Li, Y., Orr, J. E., Jen, R., Sands, S. A., Edwards, B. A., DeYoung, P. N., Owens, R. L., & Malhotra, A. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.02.074 · Cited by 21
Tiger, M., Svensson, J. E., Liberg, B., Saijo, T., Schain, M., Halldin, C., Farde, L., & Lundberg, J. (2020) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12980 · Cited by 20
Self-citationLopresti, B. J., Royse, S. K., Mathis, C. A., Tollefson, S., & Narendran, R. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15615 · Cited by 16
Donatis, D. D., Porcelli, S., Zernig, G., Mercolini, L., Giupponi, G., Serretti, A., Conca, A., & Florio, V. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2021.1938668 · Cited by 15
Kato, M., Asami, Y., Wajsbrot, D., Wang, X., Boucher, M., Prieto, R., & Pappadopulos, E. A. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.06.011 · Cited by 15
Self-citationHart, X. M., Spangemacher, M., Defert, J., Uchida, H., & Gründer, G. (2024) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001142 · Cited by 14
Shi, Z., Luan, J., Zhang, Y., Wang, G., Mei, C., Chen, L., Zhou, W., Xiong, C., Huang, T., Zhan, J., et al. (2025) · Nutrients · doi:10.3390/nu17193037 · Cited by 13
“Other antidepressants include selective 5-HT reuptake inhibitors (SSRIs), fluoxetine, sertraline, paroxetine, and escitalopram [10]; serotonin–norepinephrine (NE) re-uptake inhibitors (SNRIs) include milnacipran, duloxetine (DXT), desvenlafaxine succinate (DVS), and venlafaxine [11].”
Son, Y., Kim, Y.-B., Kim, J., Kim, J.-H., Kwon, D.-H., Lee, H., & Cho, Z. (2022) · Pharmaceuticals · doi:10.3390/ph15050583 · Cited by 12
“Two PET studies investigated the NET levels in patients with MDD and healthy controls using (S,S)-[18F]FMeNER-D2 PET [69,70].”
BackgroundMethodImpact of Venlafaxine on Platelet Count and Activity—Case Report and Narrative Review
Smolarczyk, J., Kosowski, M., Kunert, Ł., Filipczyk, K., Wojciechowski, M., Piegza, M. J., Gorczyca, P. W., Okopień, B., & Pudło, R. (2022) · Medicina · doi:10.3390/medicina58050626 · Cited by 11
“At higher doses (higher than 225 mg), it causes an increase in noradrenergic transmission [8,9].”
BackgroundGPR120 internalization: a key mechanism for EPA in antidepressant action
Yu, Q., Li, H., Chen, M., Pan, Y., Zhou, L., An, L., Zhao, J., Bai, S., Liang, Q., Zhang, R., et al. (2025) · Food & Function · doi:10.1039/d5fo00252d · Cited by 10
Cattarinussi, G., Delvecchio, G., Moltrasio, C., Ferro, A., Sambataro, F., & Brambilla, P. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.04.050 · Cited by 10
Schoretsanitis, G., Haen, E., Gründer, G., Hiemke, C., Endres, K., Ridders, F., Correll, C. U., & Paulzen, M. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02675-4 · Cited by 10
Couderc, S., Mory, C., Darnaud, L., & Saint‐Marcoux, F. (2021) · Therapies · doi:10.1016/j.therap.2021.01.052 · Cited by 8
Apathy symptoms induced by low‐dose venlafaxine: Two cases
Sato, S., Sodeyama, N., Matsuzaki, A., & Shiratori, Y. (2020) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12104 · Cited by 6
Chen, S., Zhang, J., Wu, G., Ouyang, X., Liu, Z., Lv, D., Han, Z., Xiang, Y., Chen, T., Xu, C., et al. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.05.010 · Cited by 4
An Overview of Machine Learning Applications in Mood Disorders
Topolski, N., Jeong, S. H., & Mwangi, B. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.017 · Cited by 4
Mood Disorders: Brain Imaging and Therapeutic Implications
(2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018 · Cited by 3
Nogami, T., Arakawa, R., Sakayori, T., Ikeda, Y., Okubo, Y., & Tateno, A. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.799319 · Cited by 3
Self-citationThe clinical utility of newer antidepressant agents: Understanding the role in management of MDD
Waters, K. (2022) · Mental Health Clinician · doi:10.9740/mhc.2022.10.309 · Cited by 3
“Similar results may be expected in relation to NE-related symptoms because venlafaxine XR also inhibits the reuptake of NE in a dose-dependent manner.(83) Although not always the case, the majority of patients also do respond to reinstatement of an antidepressant that was previously effective.”
ResultGeneral Principles of Pharmacologic Therapy
Inada, K., Yamawaki, S., Kanba, S., Shinozaki, G., & Kasper, S. F. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_128 · Cited by 2
Schmiedl, S. J. C., Ortega, B. A., Sosa-Moscoso, B., de Armas, G. G., Galarza, J. I. M., Rodas, J. A., & León-Rojas, J. E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031267 · Cited by 2
“Reduced serotonin receptor availability or transporter binding, altered dopamine transporter density, and changes in norepinephrine transporter occupancy suggest impaired neuromodulatory regulation of these networks [23,28,30,32,37,38].”
Trajectories of late-life depression: insights from molecular imaging
Holmes, S. E., & Smith, G. S. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02340-2 · Cited by 2
Neuroimaging Studies of Effects of Psychotherapy in Depression
Bauer, I. E., & Meyer, T. D. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.021 · Cited by 2
Electrophysiological Biomarkers for Mood Disorders
Ramakrishnan, N., Murphy, N., Selvaraj, S., & Cho, R. Y. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.015 · Cited by 2
Appel, L., Risinger, R. C., Wall, A. E., Murck, H., Liu, S., Antoni, G., & Lane, R. M. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06861-4 · Cited by 1
“However, in recent years, some clinical studies report NET occupancies (Arakawa et al. 2019; Matuskey et al. 2023) due to the development of novel CNS NET targeting radiotracers and advances in PET scanner technology (Chen et al. 2020) as well as evolved quantification methods.”
Liu, Y., Liu, L., Deng, Z., Zhou, Y., Xiao, L., & Tang, Y. (2025) · Fundamental Research · doi:10.1016/j.fmre.2025.09.024 · Cited by 1
“Since the 1950s, when chlorpromazine was recognized as an effective treatment for mental disorders [ 2 ], pharmacological therapies have remained the primary approach.”
Brain Imaging and the Mechanisms of Antidepressant Action
Godlewska, B. R., Selvaraj, S., & Cowen, P. J. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.020 · Cited by 1
Effects of Lithium on Brain Structure in Bipolar Disorder
Kaur, J., Kafantaris, V., & Szeszko, P. R. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.018 · Cited by 1
Functional Connectome in Bipolar Disorder
Cha, J., & Anand, A. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.008 · Cited by 1
Tiger, M., & Lundberg, J. (2022) · Neuromethods · doi:10.1007/978-1-0716-2083-0_11 · Cited by 1
Self-citationKasperk, N., Haen, E., Hiemke, C., Frodl, T., Schoretsanitis, G., Paulzen, M., & Kuzo, N. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2314211 · Cited by 1
“Fourth, it is essential to recognize that plasma drug concentrations may not consistently align with drug concentrations at the receptor site [35].”
BackgroundBoutari, C., Zarkada, E., Vyzantiadis, A., Vlachaki, E., Mantzou, G., Karipidou, C., & Theodoridou, S. (2024) · Acta Haematologica · doi:10.1159/000538652 · Cited by 1
“Nevertheless, VEN increases noradrenergic transmission at higher dosages (more than 225 mg) [7, 8].”
Chapter 19. Venlafaxine and Desvenlafaxine
Thase, M. E. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as19 · Cited by 1
Imaging Genetic and Epigenetic Markers in Mood Disorders
Poletti, S., Mazza, E. A., Vai, B., & Benedetti, F. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.012
Brain Imaging of Reward Dysfunction in Unipolar and Bipolar Disorders
Kumar, P., Jiang, Y., & Whitton, A. E. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.006
Resting-State Functional Connectivity in Unipolar Depression
Chen, Z., & Gong, Q. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.007
Brain Imaging Methods in Mood Disorders
Selvaraj, S., Brambilla, P., & Soares, J. C. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.002
Kious, B. M., & Renshaw, P. F. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.009
Neuroimaging Brain Inflammation in Mood Disorders
Meyer, J. H. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.011
Functional Near-Infrared Spectroscopy Studies in Mood Disorders
Matsuo, K., & Matsubara, T. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.014
Neuroanatomical Findings in Unipolar Depression and the Role of the Hippocampus
Arnone, D. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.003
Neuroimaging Biomarkers in Pediatric Mood Disorders
West, M. P., Tang, W. J., & Singh, M. K. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.005
fMRI Neurofeedback as Treatment for Depression
Skottnik, L., & Linden, D. E. J. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.013
Neuroanatomical Findings in Bipolar Disorder
Tronchin, G., & McDonald, C. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.004
Imaging Glutamatergic and GABAergic Abnormalities in Mood Disorders
Scotti-Muzzi, E., Otaduy, M. C. G., Soeiro‐de‐Souza, M. G., & Machado‐Vieira, R. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.010
Molecular Imaging of Dopamine and Antipsychotics in Bipolar Disorder
Jauhar, S. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.019
Magnetoencephalography Studies in Mood Disorders
Nugent, A. C. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.016
Selvaraj, S., Brambilla, P., & Soares, J. C. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.022
Selvaraj, S., Brambilla, P., & Soares, J. C. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.001
Experimental Medicine Approaches in Early-Phase CNS Drug Development
English, B. A., & Ereshefsky, L. (2023) · Advances in neurobiology · doi:10.1007/978-3-031-21054-9_17
General Principles of Pharmacologic Therapy
Inada, K., Yamawaki, S., Kanba, S., Shinozaki, G., & Kasper, S. F. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_128-1
Unveiling the Path to Healing: A Comprehensive Examination of Current PTSD Treatment Strategies
Barua, R., Bhowmik, S., & Datta, S. (2024) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/979-8-3693-2089-1.ch005
Barriers to Safely Discontinuing Duloxetine: An Urgent Call to Action
Shapiro, B. B., & Cohrs, D. (2025) · CNS Drugs · doi:10.1007/s40263-025-01208-1
“However, this approach has not been reported for discontinuing duloxetine, which has different pharmacologic properties than venlafaxine, including greater NET occupancy at equivalent doses (30% occupancy at 20 mg/day for duloxetine compared with 10–23% at 37.5 mg/day for venlafaxine) [32].”
InfluentialLi, L., Ren, X., & Yuan, C. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1721852
Functional and molecular brainstem imaging
Jacobs, H. I. L., Prokopiou, P. C., & Singhal, T. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-443-15736-3.00009-3
Johnston, C. H., Majoka, M. A., Macaluso, M., & Wilkinson, S. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894551913.lg02
Omori, W., Oga, K., Masuda, Y., & Okada, G. (2026) · Clinical Case Reports · doi:10.1002/ccr3.73120
Aboukaoud, M., Hoch, B., & Amiaz, R. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261470450
“…has emerged as the gold standard for measuring NET occupancy in vivo, providing direct quantification of target engagement in the human brain (Arakawa et al., 2019; Ding et al., 2014; Moriguchi et al., 2025; Nogami et al., 2013; Nyberg et al., 2013; Scherf-Clavel et al., 2020; Sekine et al.,…”
Nogami, T., Arakawa, R., Sakayori, T., Ikeda, Y., Okubo, Y., & Tateno, A. (2022) · doi:10.3389/fpsyt.2022.799319.s001
Self-citation
Metadata
- Authors
- Arakawa, R., Stenkrona, P., Takano, A., Svensson, J., Andersson, M., Nag, S., Asami, Y., Hirano, Y., Halldin, C., & Lundberg, J.
- Affiliations
- Region Stockholm (SE)
- Pfizer (Japan) (JP)
- Corresponding author
- Arakawa, Ryosuke
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-01-11
- Volume
- 22
- Issue
- 4
- Pages
- 278-285
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC6441126
- OpenAlex
- W2910200143
- Cited by
- 70
- References
- 46
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 9 · 2023: 3 · 2022: 8 · 2021: 27 · 2020: 8 · 2019: 1
- FWCI
- 6.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Swedish Research Council
- Pfizer Japan Inc.
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- venlafaxine extended release, norepinephrine transporter, major depressive disorder, binding potential, serotonin transporter, antidepressant mechanism, dose-dependent binding
- MeSH terms
- Serotonin and Noradrenaline Reuptake Inhibitors, Venlafaxine Hydrochloride, Adult, Aged, Brain, Delayed-Action Preparations, Major Depressive Disorder, Female, Humans, Male, Middle Aged, Morpholines, Positron-Emission Tomography, Norepinephrine Plasma Membrane Transport Proteins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.